Structure Therapeutics (GPCR) Expected to Announce Earnings on Friday

Structure Therapeutics (NASDAQ:GPCR) is projected to issue its quarterly earnings data before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Up 4.3 %

GPCR stock opened at $21.42 on Thursday. The firm has a 50 day moving average of $25.60 and a 200 day moving average of $32.66. The stock has a market capitalization of $1.23 billion, a PE ratio of -28.95 and a beta of -2.35. Structure Therapeutics has a 52 week low of $19.39 and a 52 week high of $62.74.

Analyst Ratings Changes

A number of equities analysts have issued reports on GPCR shares. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Finally, William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.